Seminars in Hematology
Volume 47 , Pages S8-S10 , April 2010

Enhancing Existing Approaches to Peripheral T-Cell Lymphoma

  • Francine M. Foss

      Affiliations

    • Corresponding Author InformationAddress correspondence to Francine M. Foss, MD, Yale University School of Medicine, 333 Cedar St, Suite FMP130, New Haven, CT 06510

References 

  1. Abouyabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstr 3452]. Blood. 2007;110:1011a
  2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130
  3. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289
  4. Bouabdallah R, Delmer A, Xerri L, Mounier N, Reyes F. ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: a GELA phase II trial of feasibility and efficacy [abstr 322]. Ann Oncol. 2005;16:v131
  5. Arkenau HT, Chong G, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica. 2007;92:271–272
  6. Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J. 2007;37:760–766
  7. Kim JG, Sohn SK, Chae YS, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol. 2006;58:35–39
  8. Delmer A, Fitoussi O, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [abstr 8553]. J Clin Oncol. 2009;27:447s
  9. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–2323
  10. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma [abstr 4740]. Blood. 2006;108:268b
  11. Foss F, Sjak-Shie N, Goy A, et al. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial [abstr 3449]. Blood. 2007;110:1011a
  12. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007;136:439–447
  13. Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2006;47:1274–1282
  14. Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W. Long-term outcomes of patients with newly diagnosed NK/T-cell lymphoma treated by EPOCH regimen [abstr 2689]. Blood. 2009;114:1052
  15. Jaccard A, Gachard N, Coppo P, et al. A prospective phase II trial of an L-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK/T-cell lymphoma [abstr 579]. Blood. 2008;112:217
  16. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–1020
  17. Reimer P, Ruediger T, Schertlin T, et al. Autologous stem cell transplanation as first line therapy in peripheral T cell lymphomas (Update of a prospective multicenter study [abstr 904]). Blood. 2004;104:258a
  18. Sieniawski M, Lennard J, Millar C, et al. Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens [abstr 1660]. Blood. 2009;114:662

 STATEMENT OF CONFLICT OF INTEREST: Dr Foss discloses the following relationships: Consulting Fees: Gloucester; Speaker's Bureaus: Merck, Cephalon, Eisai, Biogen; Honoraria: Eisai, Gloucester.

PII: S0037-1963(10)00013-2

doi: 10.1053/j.seminhematol.2010.01.012

Seminars in Hematology
Volume 47 , Pages S8-S10 , April 2010

Article Tools